Elevation Oncology
Dr. Alexander Drilon is the Acting Chief of the Early Drug Development Service and a medical oncologist on the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York. His research focuses on the development of targeted therapy for genomic subsets of lung cancer and other solid tumors, including cancers that harbor fusions involving ALK, ROS1, RET, and NTRK1/2/3, and MET exon 14 skipping alterations. He is a recipient of American Society for Clinical Oncology (ASCO)/Conquer Cancer Foundation Career Development and Young Investigator Awards, and grants from the International Association for the Study of Lung Cancer and the Lung Cancer Research Foundation. Dr. Drilon is also a member of the Editorial Board of ASCO University.
This person is not in the org chart
This person is not in any offices
Elevation Oncology
Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. They make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease.